In a cohort of 33 patients with CLL, an RNA sequencing dataset of CD19-CAR T cell products revealed that the expression of DNMT3A-targeted genes was significantly higher in responder patients, correlating with 65- to 635-fold enhanced expansion of CAR T cells after infusion [38]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.